AMD

According to the company, it is working with the FDA to address the agency’s issues.

The geographic atrophy treatment was approved by the FDA in the US earlier this month.

The study met its primary efficacy endpoint for the neovascular age-related macular degeneration (nAMD) treatment.

Megan Baldwin, PhD, CEO and managing director of Opthea Limited, spoke with our team about the company's clinical trial drug OPT-302 (sozinibercept) at the 2023 ASRS annual meeting.

At the 2023 ASRS annual meeting, Nancy Lurker, Executive Vice-Chair of the Board of EyePoint Pharmaceuticals, discussed the subgroup analyses of the Phase 1 DAVIO Trial of EYP-1901.

IZERVAY is expected to be available in the United States within 2 to 4 weeks.

At the 2023 ASRS annual meeting, Dante Pieramici, MD, spoke with our team to share information on OPT-302, or sozinibercept, for the treatment of neovascular AMD and other retinal vascular diseases.

In the study, researchers found that nearly one-quarter of anti-VEGF injections were received at least 1 week later than intended.

Our team caught up with Baruch Kupperman, MD, PhD to learn about his ASRS presentation, "Improving vision and dry AMD matching mechanism with the right patient population and stage of disease."

Faricimab is currently approved in more than 70 countries to treat nAMD and DME, with more than 1 million doses distributed globally, and Genentech will highlight its ophthalmology portfolio at the American Society of Retina Specialists annual meeting in Seattle.

The Biocon Biologics, Ltd product moves on to review by the European Commission, with an expected decision in late September 2023.

Dr Varun Chaudhary presents the retreatment decisions during the treat-and-extend phase of the TENAYA and LUCERNE clinical trials in neovascular AMD, focusing on the percentage of patients who maintained, extended, or reduced their treatment interval based on visual and anatomic criteria.

Dr Varun Chaudhary discusses the impact of personalized treat-and-extend-based dosing on visual and anatomic outcomes of faricimab in the TENAYA and LUCERNE clinical trials in neovascular AMD.

While these injections are the standard treatment for this patient population, the investigators found a subgroup of patients who had severe visual loss between 2 consecutive intravitreal injections.

The company announced the Complete Response Letter from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”

Dr Christiana Dinah discusses her SOE presentation, "Geographic Atrophy: A Mixed Method Study."

RGC replacement represents a more formidable challenge.

Geographic atrophy is now a major research target.

Former smokers were at higher risk of having to undergo surgery for TED in a recent study, but the risk was lower than that associated with current smoking.

A recent study aimed to set the record straight on the occurrence of retinal vein occlusions (RVOs) following messenger RNA COVID-19 vaccinations.

Dr David Almeida shares two cases of neovascular AMD from his practice, one treatment-naïve and one previously treated, and presents his findings after switching them to faricimab.

David Almeida, MD, MBA, PhD, reviews the objectives and design of the TRUCKEE study, and discusses the visual and anatomic outcomes after one and three injections of faricimab in neovascular AMD.

Findings from a recent study suggest that AO retinal imaging has the potential to become a sensitive marker for MS.

Weighing the pros and cons of anti-VEGF drugs and improved visualisation of abnormalities in ROP

The spherical equivalent was significantly more myopic in the eyes treated with laser in a recent study.

Novel treatment results in macular hole closure.

The various aspects of home monitoring for patients with age-related macular degeneration are discussed in this point/counterpoint by Prof. Rufino Silva, University of Coimbra / Coimbra Hospital and University Centre, Portugal, and Univ.-Prof. Dr. med. Robert P. Finger, PhD, Department of Ophthalmology, University of Bonn, Germany, during the 14th annual Congress on Controversies in Ophthalmology in Lisbon, Portugal.

Antonio Campos, MD, PhD, discusses his position on a discussion titled Durability Associated with Multi-target Therapies is Superior to anti-VEGF Mono-target Therapy in AMD with David Hutton, Executive Editor, Ophthalmology Times.®

Session moderators, speakers and audience members all will examine and analyse the most relevant and controversial issues within the field of ophthalmology.

A look at what’s in the therapeutic delivery pipeline for these disorders.